NCT00230282 - Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

October 31, 2011

Conditions

LeukemiaB-cell LeukemiaChronic LeukemiaChronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Alemtuzumab

3 to 30 mg, IV

DRUG

Fludarabine

\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid

DRUG

Cytoxan

(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

Trial Locations (1)

Stanford University School of Medicine, Stanford